免疫检查点抑制剂治疗头颈部皮肤鳞状细胞癌神经周围播散:是时候重新思考治疗范式了
该回顾性病例系列纳入2017年9月至2021年5月接受抗PD-1治疗的13例头颈部皮肤鳞状细胞癌伴神经周围播散患者,客观缓解率为9/13(69%),完全缓解6例(46%),部分缓解3例(23%),中位至缓解时间2.1个月,无3-4级治疗相关不良事件,支持未来开展前瞻性临床试验。
要点
- 抗PD-1治疗头颈部cSCC伴PNS的客观缓解率为69%(9/13),完全缓解率46%(6例)。
- 中位至缓解时间2.1个月(IQR 1.8-2.7个月),3例(23%)疾病进展,中位至进展时间3.5个月。
- 未观察到3-4级治疗相关不良事件。
核心结论
- 该病例系列支持抗PD-1检查点抑制剂治疗神经周围播散的积累证据,并支持未来在该患者人群中开展前瞻性临床试验。
研究设计与样本
- 回顾性综述,纳入2017年9月至2021年5月接受抗PD-1治疗的13例头颈部皮肤鳞状细胞癌伴神经周围播散患者。
主要发现
- 客观缓解见于9/13例患者(69%),其中完全缓解6例(46%),部分缓解3例(23%)。
- 中位至缓解时间为2.1个月(IQR 1.8-2.7个月)。
- 3例(23%)患者出现疾病进展,中位至进展时间为3.5个月。
- 未发生3-4级治疗相关不良事件。
关键数值与推荐
- 主要终点为客观缓解(完全或部分缓解)和中位至进展时间,由头颈多学科团队(MDT)及独立放射学对磁共振成像(MRI)和/或计算机断层扫描/正电子发射断层扫描(CT/PET)的审阅确定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors have shown promising antitumour activity. Application in head and neck cutaneous squamous cell carcinoma (cSCC) large nerve perineural spread (PNS) is limited. METHODS: Retrospective review of 13 patients with PNS receiving anti-PD-1 therapy from September 2017 to May 2021 is presented. Primary endpoints were objective response (complete or partial response) and median time to progression, determined by Head and Neck Multi-Disciplinary Team (MDT) and independent radiology review of magnetic resonance imaging (MRI) and/or computed tomography/positron emission tomography (CT/PET). RESULTS: Objective response was observed in 9/13 patients (69%), with complete response in 6 (46%) and partial response in 3 patients (23%). Median time to response was 2.1 months (IQR 1.8-2.7 months). There were 3 (23%) patients with progressive disease, with median time to progression of 3.5 months. There were no grade 3-4 treatment related adverse events. CONCLUSIONS: This case series supports developing evidence for anti-PD-1 checkpoint inhibitor therapy for perineural spread, supporting future prospective clinical trials in this patient population.
引用
- Nightingale J, Gandhi M, Helena J, et al. Immunotherapy for the treatment of perineural spread in cutaneous head and neck squamous cell carcinoma: Time to rethink treatment paradigms. Head Neck. 2022. PMID: 35156249. doi:10.1002/hed.27005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。